Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Pharmaceuticals grew +8% in Q3 with growth drivers and
launches showing strong momentum
Growth drivers and launches +32% in Q3, representing 54% of sales (up from 44% Q3 2020)
Pharmaceuticals net sales
USD bn, % cc
Launches1
Growth drivers²
Mature products³
+7%
+8%
19.7
6.7
17.9
6.1
1.7
0.6
0.4
1.0
+32%
+30%
2.3
3.0
6.6
8.4
Representing
54% of sales
3.4
3.1
10.3
9.6
-10%
-10%
Q3 2020
Q3 2021
9M 2020
9M 2021
All % growth relate to cc unless otherwise stated 1. ZolgensmaⓇ, KesimptaⓇ, MayzentⓇ, BeovuⓇ, LuxturnaⓇ, Leqvio®, Enerzair® and AtecturaⓇ 2. Cosentyx®, EntrestoⓇ, XolairⓇ, llaris®, XiidraⓇ and AimovigⓇ 3. All other brands.
24 Investor Relations | Q3 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation